vs
Side-by-side financial comparison of SITIME Corp (SITM) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
SITIME Corp is the larger business by last-quarter revenue ($113.3M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). SITIME Corp runs the higher net margin — 8.1% vs -49.0%, a 57.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 66.3%). SITIME Corp produced more free cash flow last quarter ($13.0M vs $-84.7M).
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SITM vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.3M | $70.6M |
| Net Profit | $9.2M | $-34.6M |
| Gross Margin | 56.4% | — |
| Operating Margin | 1.6% | -56.7% |
| Net Margin | 8.1% | -49.0% |
| Revenue YoY | 66.3% | 81958.1% |
| Net Profit YoY | 148.7% | 54.9% |
| EPS (diluted) | $0.44 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $113.3M | — | ||
| Q3 25 | $83.6M | $70.6M | ||
| Q2 25 | $69.5M | — | ||
| Q1 25 | $60.3M | — | ||
| Q4 24 | $68.1M | — | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $43.9M | — | ||
| Q1 24 | $33.0M | — |
| Q4 25 | $9.2M | — | ||
| Q3 25 | $-8.0M | $-34.6M | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-23.9M | — | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $-26.8M | — | ||
| Q1 24 | $-28.7M | — |
| Q4 25 | 56.4% | — | ||
| Q3 25 | 53.5% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 50.3% | — | ||
| Q4 24 | 52.6% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 49.1% | — | ||
| Q1 24 | 53.5% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | -19.2% | -56.7% | ||
| Q2 25 | -35.4% | — | ||
| Q1 25 | -46.6% | — | ||
| Q4 24 | -33.8% | — | ||
| Q3 24 | -43.1% | — | ||
| Q2 24 | -73.7% | — | ||
| Q1 24 | -106.1% | — |
| Q4 25 | 8.1% | — | ||
| Q3 25 | -9.6% | -49.0% | ||
| Q2 25 | -29.0% | — | ||
| Q1 25 | -39.6% | — | ||
| Q4 24 | -27.6% | — | ||
| Q3 24 | -33.5% | — | ||
| Q2 24 | -61.0% | — | ||
| Q1 24 | -86.9% | — |
| Q4 25 | $0.44 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $-0.84 | — | ||
| Q1 25 | $-1.01 | — | ||
| Q4 24 | $-0.80 | — | ||
| Q3 24 | $-0.83 | — | ||
| Q2 24 | $-1.16 | — | ||
| Q1 24 | $-1.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $503.0M |
| Total Assets | $1.3B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $490.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | $503.0M | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $692.5M | — | ||
| Q4 24 | $699.7M | — | ||
| Q3 24 | $696.2M | — | ||
| Q2 24 | $692.5M | — | ||
| Q1 24 | $696.2M | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $577.1M | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $872.1M | — | ||
| Q4 24 | $885.0M | — | ||
| Q3 24 | $877.9M | — | ||
| Q2 24 | $878.6M | — | ||
| Q1 24 | $942.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.4M | $-84.6M |
| Free Cash FlowOCF − Capex | $13.0M | $-84.7M |
| FCF MarginFCF / Revenue | 11.5% | -120.1% |
| Capex IntensityCapex / Revenue | 10.9% | 0.2% |
| Cash ConversionOCF / Net Profit | 2.77× | — |
| TTM Free Cash FlowTrailing 4 quarters | $35.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.4M | — | ||
| Q3 25 | $31.4M | $-84.6M | ||
| Q2 25 | $15.3M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-181.0K | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | $13.0M | — | ||
| Q3 25 | $26.3M | $-84.7M | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-1.3M | — | ||
| Q4 24 | $-2.4M | — | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-2.7M | — | ||
| Q1 24 | $-1.2M | — |
| Q4 25 | 11.5% | — | ||
| Q3 25 | 31.5% | -120.1% | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -2.1% | — | ||
| Q4 24 | -3.5% | — | ||
| Q3 24 | -11.6% | — | ||
| Q2 24 | -6.3% | — | ||
| Q1 24 | -3.6% | — |
| Q4 25 | 10.9% | — | ||
| Q3 25 | 6.1% | 0.2% | ||
| Q2 25 | 26.2% | — | ||
| Q1 25 | 27.0% | — | ||
| Q4 24 | 23.3% | — | ||
| Q3 24 | 25.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 8.8% | — |
| Q4 25 | 2.77× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
